"425516" . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . . "RIV/00216224:14110/07:00032969!RIV10-MSM-14110___" . . . "RIV/00216224:14110/07:00032969" . "\u0160r\u00E1mek, Vladim\u00EDr" . . "6"^^ . . "4"^^ . "Immodin in the treatment of immunoparalysis in intensive care patients" . "Kukl\u00EDnek, Pavel" . "\u0160\u0165oura\u010Dov\u00E1, M." . . . "CZ - \u010Cesk\u00E1 republika" . "intensive care unit patients; immunoparalysis; Immodin"@en . . . "Immodin in the treatment of immunoparalysis in intensive care patients"@cs . "Immodin in the treatment of immunoparalysis in intensive care patients"@en . "14110" . "OBJECTIVE: The objective of the study was to evaluate the effect of administration of the immunoregulating preparation Immodin (Sevapharma, CZ) to influence immunoparalysis in intensive care unit patients. METHOD: A double blind, randomised clinical study was designed for the above purpose. The patients in whom immunoparalysis was detected during monitoring (CD14+ HLA-DR+ < or = 40 %) were randomised for the administration of Immodin (IM) or placebo (PL); the treatment lasted for 5 days. 45 (25% of all monitored) patients - the men/women ratio being 29/16, 60 (54; 65) years of age - were enrolled in the study (of which 25 IM and 20 PL). RESULTS: The patients did not show differences in ICU mortality - 23 IM patients survived, 2 IM patients died; 15 PL patients survived and 5 PL patients died (p = 0.214). The time of ICU hospitalisation did not differ, either - 11.6 days for IM patients (8.2; 14.9), 12.6 days for PL patients (9.1; 16.1) (P = 0."@en . "Immodin in the treatment of immunoparalysis in intensive care patients"@cs . "Bure\u0161ov\u00E1, Lucie" . . . "OBJECTIVE: The objective of the study was to evaluate the effect of administration of the immunoregulating preparation Immodin (Sevapharma, CZ) to influence immunoparalysis in intensive care unit patients. METHOD: A double blind, randomised clinical study was designed for the above purpose. The patients in whom immunoparalysis was detected during monitoring (CD14+ HLA-DR+ < or = 40 %) were randomised for the administration of Immodin (IM) or placebo (PL); the treatment lasted for 5 days. 45 (25% of all monitored) patients - the men/women ratio being 29/16, 60 (54; 65) years of age - were enrolled in the study (of which 25 IM and 20 PL). RESULTS: The patients did not show differences in ICU mortality - 23 IM patients survived, 2 IM patients died; 15 PL patients survived and 5 PL patients died (p = 0.214). The time of ICU hospitalisation did not differ, either - 11.6 days for IM patients (8.2; 14.9), 12.6 days for PL patients (9.1; 16.1) (P = 0." . "6"^^ . "\u0160\u0165etka, P." . "53" . "Immodin in the treatment of immunoparalysis in intensive care patients" . "9" . "OBJECTIVE: The objective of the study was to evaluate the effect of administration of the immunoregulating preparation Immodin (Sevapharma, CZ) to influence immunoparalysis in intensive care unit patients. METHOD: A double blind, randomised clinical study was designed for the above purpose. The patients in whom immunoparalysis was detected during monitoring (CD14+ HLA-DR+ < or = 40 %) were randomised for the administration of Immodin (IM) or placebo (PL); the treatment lasted for 5 days. 45 (25% of all monitored) patients - the men/women ratio being 29/16, 60 (54; 65) years of age - were enrolled in the study (of which 25 IM and 20 PL). RESULTS: The patients did not show differences in ICU mortality - 23 IM patients survived, 2 IM patients died; 15 PL patients survived and 5 PL patients died (p = 0.214). The time of ICU hospitalisation did not differ, either - 11.6 days for IM patients (8.2; 14.9), 12.6 days for PL patients (9.1; 16.1) (P = 0."@cs . . . . . . "Dad\u00E1k, Luk\u00E1\u0161" . "[ABA00187CBC3]" . "Immodin in the treatment of immunoparalysis in intensive care patients"@en . "V" . . "0042-773X" .